TY - JOUR
T1 - The interplay of endocrine therapy, steroid pathways and therapeutic resistance
T2 - Importance of androgen in breast carcinoma
AU - Takagi, Kiyoshi
AU - Miki, Yasuhiro
AU - Ishida, Takanori
AU - Sasano, Hironobu
AU - Suzuki, Takashi
N1 - Funding Information:
This work was partly supported by JSPS KAKENHI Grant Number 16K08645 . Microarray data of breast carcinomas treated with exemestane was kindly provided from Dr. Izo Kimijima (Northern Fukushima Medical Center, Breast Center, Fukushima, Japan).
Publisher Copyright:
© 2017
PY - 2018/5/5
Y1 - 2018/5/5
N2 - A great majority of breast carcinomas expresses estrogen receptor (ER) and estrogens have crucial roles in the progress of breast carcinomas. Endocrine therapy targeting ER and/or intratumoral estrogen production significantly improved clinical outcomes of the patients with ER-positive breast carcinomas. However, resistance to endocrine therapy is often observed and significant number of patients will recur after the treatment. In addition, treatment for the patients with triple-negative breast carcinomas (negative for all ER, progesterone receptor (PR) and HER2) are limited to cytotoxic chemotherapy and novel therapeutic targets need to be identified. In breast carcinoma tissues, not only ER but androgen receptor (AR) is frequently expressed, suggesting pivotal roles of androgens in the progress of breast carcinomas. Growing interest on androgen action as possible therapeutic target has been taken, but androgen action seems quite complicated in breast carcinomas and inconsistent findings has been also proposed. In this review, we will summarize recent studies regarding intratumoral androgen production and its regulation as well as distinct subset of breast carcinomas characterized by activated AR signaling and recent clinical trial targeting AR in the patients with either ER-positive and ER-negative breast carcinomas.
AB - A great majority of breast carcinomas expresses estrogen receptor (ER) and estrogens have crucial roles in the progress of breast carcinomas. Endocrine therapy targeting ER and/or intratumoral estrogen production significantly improved clinical outcomes of the patients with ER-positive breast carcinomas. However, resistance to endocrine therapy is often observed and significant number of patients will recur after the treatment. In addition, treatment for the patients with triple-negative breast carcinomas (negative for all ER, progesterone receptor (PR) and HER2) are limited to cytotoxic chemotherapy and novel therapeutic targets need to be identified. In breast carcinoma tissues, not only ER but androgen receptor (AR) is frequently expressed, suggesting pivotal roles of androgens in the progress of breast carcinomas. Growing interest on androgen action as possible therapeutic target has been taken, but androgen action seems quite complicated in breast carcinomas and inconsistent findings has been also proposed. In this review, we will summarize recent studies regarding intratumoral androgen production and its regulation as well as distinct subset of breast carcinomas characterized by activated AR signaling and recent clinical trial targeting AR in the patients with either ER-positive and ER-negative breast carcinomas.
KW - Androgens
KW - Breast cancer
KW - Endocrine resistance
UR - http://www.scopus.com/inward/record.url?scp=85029480004&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85029480004&partnerID=8YFLogxK
U2 - 10.1016/j.mce.2017.09.011
DO - 10.1016/j.mce.2017.09.011
M3 - Review article
C2 - 28918115
AN - SCOPUS:85029480004
VL - 466
SP - 31
EP - 37
JO - Molecular and Cellular Endocrinology
JF - Molecular and Cellular Endocrinology
SN - 0303-7207
ER -